News & Events
17 September 2026
Portfolio company EcoPhage, a leader in sustainable phage-based biopesticides, has received U.S. Environmental Protection Agency (“EPA”) approval for GoldenEco®. GoldenEco is a targeted biopesticide developed to address destructive bacterial diseases in tomatoes and peppers caused by Xanthomonas and Pseudomonas. The approval opens the commercialization pathway for GoldenEco in the United States, subject to applicable state registrations and other requirements.
Bacterial diseases remain a major operational challenge for tomato and pepper growers, with conventional crop management relying heavily on chemical and metal-based treatments. Heightened regulatory scrutiny, environmental concerns, pathogen resistance, and rising demand for sustainable farming practices are driving the market toward effective biological solutions. GoldenEco leverages EcoPhage’s proprietary bacteriophage technology to deploy naturally occurring phages that specifically target and destroy bacterial pathogens without chemical residues.
GoldenEco represents the first product in EcoPhage’s platform to achieve U.S. commercial entry, proving the company’s ability to advance phage-based biopesticides from research and development through rigorous regulatory review.
Following the EPA approval, EcoPhage will execute its commercial roll-out by collaborating with U.S. commercial partners, distributors, and growers to prepare for market development and distribution.
Receiving EPA approval for GoldenEco® is a major achievement for EcoPhage and an important milestone in our commercialization strategy. After years of research, development, field testing, and regulatory work, we are now ready to bring GoldenEco® to U.S. growers. This approval validates the strength of our technology platform and represents an important step toward providing growers with new biological tools to manage bacterial diseases in high-value crops.
Guy Elitzur, CEO of EcoPhage
This regulatory milestone demonstrates EcoPhage’s technical leadership and its capability to execute a successful regulatory strategy toward commercial entry in the U.S. market.
Haim Brosh, Executive Director and CEO of The Trendlines Group
We believe this EPA approval significantly strengthens EcoPhage’s growth trajectory and longterm value creation potential in sustainable crop protection. Trendlines remains a committed shareholder supporting EcoPhage’s commercialization efforts.
Nitza Kardish, PhD, EVP Head of Agrifood, The Trendlines Group
Escala Secures $4.5M in Funding to Accelerate Global Expansion of Its FDA-Approved Medical Device
Co-financing by the EIC Fund to ramp up women’s health solution to POP
Phytolon Secures Funding from Rich Products Ventures to Bring Natural Food Colors to Market